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Abstract: Hyperreactivity to stress may be one explanation for the increased risk of cardiovascular
disease (CVD) in individuals with essential hypertension. We investigated blood lipid reactivity to
the Montreal Imaging Stress Task (MIST), a psychosocial stressor, in hypertensive and normotensive
men and tested for prospective associations with biological risk factors. Fifty-six otherwise healthy
and medication-free hypertensive and normotensive men underwent the MIST. We repeatedly
measured cortisol and blood lipid profiles (total cholesterol (TC), low-density lipoprotein cholesterol
(LDL-C), high-density lipoprotein cholesterol (HDL-C), and triglycerides (TG)) immediately before
and up to 1 h after stress. Lipid levels were corrected for stress hemoconcentration. Thirty-five
participants completed follow-up assessment 2.9 ± 0.12 (SEM) years later. CVD risk was assessed
by prospective changes in TC/HDL-C ratio, IL-6, D-dimer, and HbA1c from baseline to follow-up.
The MIST induced significant changes in all parameters except TC (p-values ≤ 0.043). Compared
with normotensives, hypertensives had higher TC/HDL-C-ratio and TG (p-values ≤ 0.049) stress
responses. Blood lipid stress reactivity predicted future cardiovascular risk (p = 0.036) with increases
in HbA1c (ß = 0.34, p = 0.046), IL-6 (ß = 0.31, p = 0.075), and D-dimer (ß = 0.33, p = 0.050). Our results
suggest that the greater blood lipid reactivity to psychosocial stress in hypertensives, the greater their
future biological CVD risk. This points to lipid stress reactivity as a potential mechanism through
which stress might increase CVD risk in essential hypertension.
Keywords: blood lipid stress reactivity; essential hypertension; Montreal Imaging Stress Task;
cardiovascular risk; TC/HDL-C ratio; interleukin-6; D-dimer; hemoglobin A1c
1. Introduction
Cardiovascular diseases (CVD) rank among the leading causes of death in adult-
hood [1], with hypertension being one major risk factor [2]. Most hypertensive patients are
diagnosed with essential hypertension as the medical cause for their chronically elevated
blood pressure (BP) is unclear [3,4]. Hypertension often occurs in conjunction with other
cardiovascular risk factors such as older age, obesity, insulin resistance, diabetes, and
dyslipidemia [2,4]. Especially dyslipidemia has frequently been observed in hypertensive
individuals compared to normotensive controls, including increased total cholesterol (TC),
triglycerides (TG), and low-density lipoprotein cholesterol (LDL-C) on the one hand, and
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decreased high-density lipoprotein cholesterol (HDL-C) on the other [5–7]. This adverse
lipid profile is reflected by an excess proportion of atherogenic lipoproteins over HDL-C
in hypertensives [8,9]. In particular, the TC/HDL-C ratio has been described as a suitable
index reflecting the magnitude of dyslipidemia [10] with a strong predictive value for the
incidence of both ischemic heart disease and cardiovascular risk [10,11].
Mental stress is an independent psychological risk factor for CVD [12]. According to
the stress reactivity hypothesis, the study of physiological responses to controlled short-
term challenges yields important insights into the complex psychobiological processes
involved in the development of CVD [13]. Different acute mental stressors have been
shown to elicit transient elevations in atherogenic lipids and the TC/HDL-C ratio [14–19],
although only few studies found stress-induced lipid increases independent of stress
hemoconcentration [15–17]. This is important because hemoconcentration confounds
measurement of stress-induced changes in blood lipids [20]. More precisely, stress can
induce transient acute loss of plasma volume into the extravascular space, which results in
concentration and passive increase of nondiffusible blood constituents such as lipids [18].
While studies using mild stressors did not show blood lipid increases independent of
hemoconcentration [18,19], studies with more potent stressors including psychosocial threat
elements did so [15–17]. For instance, applying the Trier Social Stress Test (TSST) [21],
which combines public speaking and mental arithmetic to be delivered in front of an
audience, we found increased TC and LDL-C responses in hypertensives compared to
normotensives [17]. These results suggest hyperreactivity of atherogenic lipids to stress
in hypertensives. Similar to the TSST, the Montreal Imaging Stress Task (MIST) is a
psychosocial stressor that comprises motivated performance with social evaluative threat
and uncontrollability [22]. So far, the MIST has been shown to reliably induce substantial
increases in salivary cortisol indicative of hypothalamic–pituitary–adrenal axis (HPA)
activation as well as increases in blood pressure and heart rate indicating sympathoadrenal
medullary (SAM) arousal [22,23]. Thus far, studies on blood lipid reactivity using the MIST
have not been performed.
The responsivity of blood lipids to an acute standardized stressor might contribute to
pathophysiological processes involved in the development of CVD. For instance, greater
lipid responses to acute mild stress predicted higher TC/HDL-C ratios several years later in
London-based civil servants, although stress hemoconcentration effects were not accounted
for [24]. To our best knowledge, there are no studies that have investigated prospectively
the effects of blood lipid stress reactivity on intermediate biomarkers of an increased
CVD risk, reflecting low-grade systemic chronic inflammation (interleukin (IL)-6 [25]), a
prothrombotic state (fibrin D-dimer [26]), or a diabetic condition (glycosylated hemoglobin
A1c, HbA1c [27]).
We aimed to investigate (1) whether acute psychosocial stress induced by the MIST
would induce changes in blood lipid levels independently of hemoconcentration in hy-
pertensive and normotensive participants. We hypothesized that hypertensives would
show greater stress-induced increases in TC, LDL-C, TG, and the TC/HDL-C ratio, but
reduced HDL-C compared with normotensives. Moreover, (2) to shed light on the potential
clinical relevance of higher blood lipid stress reactivity, we investigated whether reactivity
of the TC/HDL-C ratio to the MIST would predict IL-6, D-dimer, and HbA1c levels after a
follow-up of 2 to 5 years. We hypothesized higher blood lipid stress reactivity to predict
future increases in these biomarkers of atherothrombotic CVD risk.
2. Materials and Methods
2.1. Study Participants
The current investigation is part of a series of studies assessing psychoneurobiological
mechanisms in essential hypertension [28,29] approved by the ethics committee of the
State of Bern, Switzerland. All participants provided written informed consent and were
financially compensated with 140 CHF.
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With the aid of the Swiss Red Cross of the State of Bern, we recruited apparently
healthy, nonsmoking hypertensive and normotensive men of comparable age. In detail,
members of our study team accompanied the mobile blood-donation unit of the Swiss
Red Cross that routinely records BP before blood donation. Blood donors interested in
the study participation were given written information asking for the following inclusion
criteria: age between 18 and 80 years; BP either in the hypertensive or in the normotensive
range (see below); nonsmoker (<5 cigarettes per day), and no alcohol or illicit drug abuse.
Specific exclusion criteria were verified by telephone interview using an extensive health
questionnaire [28,29]. Participants were not eligible to participate when they reported
any current infectious disease, current use of medication, a diagnosis of heart disease,
elevated cholesterol, elevated blood sugar and diabetes, liver and renal diseases, chronic
obstructive pulmonary disease, rheumatic diseases, HIV, cancer, chronic or acute clinical
psychiatric disorders, as well as regular strenuous physical exercise, tobacco consumption,
excessive alcohol, and illicit drug abuse. Four eligible participants (one normotensive
and three hypertensives) who reported regular medication intake stopped taking their
medication 1 week prior to the study. Eligible hypertensive participants provided blood
samples for the routine assessment of serum creatinine, calcium, sodium, and potassium to
exclude potential cases with secondary hypertension. Due to technical problems, sodium,
potassium, and calcium could not be analyzed in five hypertensive participants. In one
of these participants, creatinine could not be measured either. No eligible hypertensive
participant was diagnosed with secondary hypertension. We measured HbA1c and blood
lipids (see below) in all participants.
2.2. Classification of Essential Hypertension and Normotension
Classification of essential hypertension and normotension was based on a two-step
assessment procedure. In step 1, following written instructions, interested blood donors
were asked to measure their BP on three days at home using sphygmomanometry (Omron
M6; Omron Healthcare Europe B.V., Hoofdorp, Netherlands). Home BP was to be self-
measured once in the morning and once in the evening in a seated position, each after
a 15-min rest. Participants were recruited as hypertensive if the average home systolic
blood pressure (SBP) was ≥135 mmHg and/or the average home diastolic blood pressure
(DBP) was ≥85 mmHg according to recommendations for home BP measurements [30].
Correspondingly, participants were recruited as normotensives if the average home SBP
was <135 mmHg and the average home DBP was <85 mmHg. We computed the average
home BP of the six measurements obtained by each participant. Home BP measurement
was provided by a total of 63 potential participants. Two participants were diagnosed
with essential hypertension prior to their study participation and did not perform home
measurements.
In step 2, we verified the home-measurement-based preliminary classification of
each of these participants as hypertensive or normotensive. Trained personnel performed
three additional BP measurements during the first study session with the participant in
a seated position after a 15-min rest. We applied the regular World Health Organization
(WHO)/International Society of Hypertension (ISH) definition of hypertension and clas-
sified medication-free participants as hypertensive if their average study SBP was ≥140
mmHg and/or their average study DBP was ≥90 mmHg [31]. Participants were classified
as normotensive if their average study SBP was <140 mmHg and their average study DBP
was <90 mmHg.
The final group assignment of medication-free participants was based on congruent
home and study BP classification and comprised 28 normotensives and 28 essential hyper-
tensives. Six participants were excluded due to normotensive home, but hypertensive study
BP (white coat hypertension), and three participants were excluded due to hypertensive
home and normotensive study BP (masked hypertension).
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2.3. Design and Procedure
Cross-sectional data assessment comprised 2 days. On the 1st study day, we performed
study BP classification to verify the home-measurement-based preliminary classification
of hypertension and normotension and to assess medical information. Hypertensive and
normotensive participants with congruent home and study BP classification were then
invited to a 2nd study day to undergo a standardized stress test.
2.3.1. First Study Day and Baseline CVD Risk Assessment
All participants consumed a semistandardized breakfast following written instructions
and abstained from caffeine and alcohol consumption for 24 h prior to their arrival at the
lab at 8:00. After providing written informed consent, participants´ body measurements
(height and weight) were assessed. Resting study BP was assessed three times by means of
sphygmomanometry (Omron M6; Omron Healthcare Europe B.V., Hoofdorp, Netherlands),
each after a 15-min rest period. Blood samples were collected at 11:30, i.e., after a fasting
for 3.5 h since arrival. Due to technical problems, baseline blood sampling was missing in
one hypertensive participant and incomplete in one normotensive participant.
2.3.2. Second Study Day and Stress Reactivity Assessment
All participants were instructed to abstain from food for at least 1 h, and from alcoholic
and caffeinated beverages and strenuous exercise for at least 24 h before the second study
appointment. They were further required to be well rested and to have maintained a
regular sleep–wake rhythm for three nights before the reactivity testing. Participants
arrived between 12:00 and 13:00 at the lab, where they received detailed explanations of
the testing procedure and provided informed consent for the 2nd study day. Then, trained
study nurses inserted an intravenous catheter into the participants’ nondominant forearm
for blood sampling. During the following 45-min acclimatization period, participants
completed psychosocial questionnaires ahead of the collection of baseline blood samples.
Afterwards, participants underwent a standardized psychosocial laboratory stressor for
imaging studies (i.e., the MIST) as explained below. The recovery period started after
cessation of the stressor and lasted for 1 h. Blood and saliva samples were collected
immediately before stress induction by the MIST (−1 min) and repeatedly after MIST
cessation (+1 min, +10 min, +20 min, and +60 min). Additional saliva samples were assessed
30 and 45 min after stress. Participants were in supine position during the experimental
procedure, and all blood samples were drawn in supine position. Participants only raised
to move from the test room to the nearby scanner room (after MIST baseline blood sample)
and back again (after blood sample +1 min). They were also unrestricted to visit the
restrooms at any time.
2.3.3. Assessment of CVD Risk at Follow-Up
To assess longitudinal changes in CVD risk factors, we invited our study participants
to a follow-up assessment at least 2 years later for blood sampling procedures identical
to the 1st study day. All 56 participants of the baseline assessment were invited for the
follow-up assessment scheduled between 2 and 5 (M = 2.86 ± 0.12) years later, with a final
sample of 35 participants completing both assessments. Reasons for drop-out comprised
severe illness (n = 4), no interest (n = 2), not reachable by phone (n = 5), lack of time (n = 5),
excessive demand (n = 1), or no reason given (n = 4). Notably, we initially intended to
schedule for a 2-year follow-up period. However, due to the relocation of the working
group from Bern (Switzerland) to Konstanz (Germany), the follow-up assessments in Bern
were hampered by limited personnel resources and logistic challenges. This resulted in
substantially longer follow-up intervals with potential effects on drop-out rates.
2.4. Montreal Imaging Stress Task (MIST)
Psychosocial stress was induced following the standard protocol of the MIST. This
standardized stress paradigm was developed for functional imaging studies and reliably
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induces psychophysiological stress responses [22]. The MIST is based on the Trier Mental
Challenge Task, and combines a series of computerized mental arithmetic challenges with
social evaluative threat components [32]. The MIST was carried out with (stress condition)
or without (control condition) time pressure and social evaluation.
In detail, starting with a training session, participants’ ability to perform mental
arithmetic was assessed outside the scanner, and the average time needed to solve problems
was used to set a default time limit for the experimental condition. In both conditions (stress
and control), participants had to solve mental arithmetic tasks presented on a projection
screen, which additionally displayed performance feedback (i.e., correct, incorrect, or
time out). Stress was induced by consistently adapting the difficulty and time provided
to solve the mental arithmetic to ensure a 50% to 60% failure rate. Simultaneously, a
continuous performance progress bar on the screen indicated to the participants that
their performance was weaker compared to that of all other participants of similar age,
educational level, and professional position. Between runs, two confederates, introduced
as study investigator and as study leader, enforced social evaluative threat by giving
standardized fake feedback [22].
As first feedback, the study investigator reminded the participant that there is a re-
quired minimum performance for the participant to be used in the analysis of the functional
scan. The investigator informed the participant that the scanning session had to be stopped
because of his poor performance. The investigator also asked about potential reasons
for this poor performance (e.g., problems with understanding the task, problems with
the response box, or visual problems with the screen). Finally, the participant was told
that the study investigator, the study leader, and the MR technicians were following his
performance on a second monitor in the control room of the scanning environment and
asked him to give his best to provide useful data. The investigator then left the scanner
room, and the next run of mental arithmetic was initiated.
The second feedback was given by the supposed leader of the study. The latter
informed the participant that his performance had been monitored and that the scanning
session had to be stopped again because of his poor performance. The study leader asked
the participant if he was aware of his below-average performance. He reminded the
participant that his performance should at least approach the average user level if his
data were to be used in the study. Since he had often exceeded the time provided to
solve the mental arithmetic (as indicated by “timeout”), the participant was also asked
about potential problems with concentration in the last days or any alcohol intake during
the last 24 h. Finally, the participant was asked to try his best to provide useful data; the
investigator further explained that useful data were naturally the primary goal of the whole
study team since a lot of energy and money had already been spent on the participants’
fMRI data acquisition. Then, the third run of mental arithmetic was initiated.
The control condition consisted of mental arithmetic tasks with comparable difficulty
level but presented without any time restriction and/or negative feedback. Individual and
average users’ performance were not displayed.
In total, the participants underwent three runs. In each run, the stress (105 s) and the
non-stress (45 s) conditions were presented in a blocked design with three repetitions in a
counterbalanced order. The two feedbacks were given between runs 1 and 2 (feedback 1),
and between runs 2 and 3 (feedback 2). The total duration of the MIST was about 30 min.
2.5. Biochemical Analyses
2.5.1. Blood Lipids
Blood lipid profiles were assessed on all three study days. On study day 2, measure-
ments were immediately before and after stress, as well as 10, 20, and 60 min after stress
cessation (−1 min, +1 min, +10 min, +20 min, and +60 min). We repeatedly measured total
TC and HDL-C to allow computation of TC/HDL-C ratio [10], as well as TG from heparine-
coated monovettes (Sarstedt monovette orange). Analyses were performed at the Center for
Laboratory Medicine of the Bern University Hospital (Inselgruppe AG, Bern, Switzerland)
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using in vitro assays (enzymatic colorimetric) for the quantitative determination of blood
lipids in human plasma (Roche, Mannheim, Germany) on a Roche/Hitachi Cobas C Ana-
lyzer (Roche, Mannheim, Germany). LDL-C was calculated using the Friedewald formula:
LDL-C = TC − HDL-C − (TG/2.19). Mean inter- and intra-assay CVs were ≤1.2% and
≤2.5%, respectively. In order to correct plasma lipid levels for stress hemoconcentration,
we additionally assessed hemoglobin (grams per deciliter) and hematocrit (percentage)
by processing whole blood collected in 2.7 mL EDTA-coated tubes (Sarstedt, Nümbrecht,
Germany) on an automated hematology system (Advia 120, Siemens Diagnostics, Erlangen,
Germany) at the Center for Laboratory Medicine. Due to technical problems with blood
sampling, baseline (i.e., day 1) blood lipids were missing in one hypertensive and one
normotensive participant.
2.5.2. Cortisol
We measured cortisol as a manipulation check to test whether the MIST successfully
induced cortisol stress reactivity as observed in previous research [22]. For assessment
of cortisol, saliva samples were collected at 7 time points (−1 min, +1 min, +10 min,
+20 min, +30 min, +45 min, and +60 min) using Salivette devices (Sarstedt, Rommelsdorf,
Germany), which were stored at −20 ◦C until biochemical analysis. Prior to analyses,
saliva samples were thawed and spun at 3000 rpm for 10 min, yielding low-viscosity
saliva. Cortisol concentrations were measured using a commercially available competitive
chemiluminescence immune assay with high sensitivity of 0.16 ng/mL (LIA, IBL Hamburg,
Germany). Intra- and inter-assay CVs were <7.7% and 11.5%, respectively. Cortisol
assessment was missing in one hypertensive participant, and cortisol data of another
normotensive participant were not considered due to an outlier value (>70 nmol/L) at
baseline.
2.5.3. CVD Risk Assessment
CVD risk was assessed in all participants at baseline and prospectively at follow-up.
We assessed CVD risk by measurement of the following risk factors: TC/HDL-C ratio, the
hypercoagulability marker D-dimer, HbA1c, as well as the pro-inflammatory cytokine IL-6.
Blood lipids, D-dimer, and HbA1c were analyzed at the Center for Laboratory Medicine of
the Bern University Hospital (Inselgruppe AG, Bern, Switzerland), while IL-6 analyses were
performed in the biochemical laboratory of the Biological Work and Health Psychology
group at the University of Konstanz.
For assessment of D-dimer, venous blood was drawn into polypropylene tubes contain-
ing 3.8% sodium citrate (Sarstedt, Nümbrecht, Germany). Citrate tubes were immediately
centrifuged for 20 min at 4 ◦C at 2000× g, and plasma was pipetted into aliquots. D-dimer
was analyzed using a particle-enhanced immunoturbidimetric assay for the quantitative
determination of D-dimer in human plasma (INNOVANCE® D-Dimer, Siemens Healthcare
GmbH, Erlangen, Germany) on a Sysmex CS-5100 (Sysmex Europe, Norderstedt, Germany).
The intra- and inter-assay coefficients of variation were ≤7.9%.
To measure HbA1c, venous blood was drawn into EDTA-coated monovettes, and
analyses were performed with in vitro assays for the quantitative determination of HbA1c
IFCC (mmol/mol) in whole blood (Tina-quant®, Roche, Mannheim, Germany) using
Roche/Hitachi Cobas C Systems (Roche, Mannheim, Germany). Mean inter- and intra-
assay CVs were ≤1.6% and ≤2.0%, respectively.
For the determination of IL-6, venous blood was drawn in EDTA-coated monovettes
(Sarstedt, Nümbrecht, Germany) and immediately centrifuged for 10 min at 2000× g and
4 ◦C. Obtained plasma was stored at −80 ◦C until analysis. IL-6 levels were determined
with a high-sensitivity sandwich immunoassay (Meso Scale Discovery (MSD), Rockville,
MD, USA). Mean inter- and intra-assay CVs were ≤7.3% and ≤4.5%, respectively, and the
detection limit was 0.06 pg/mL. Baseline measurements were incomplete in one hyperten-
sive and one normotensive participant (see Table 1 for details).
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(n = 28) p
Age (years) 49.82 ± 2.04 (25–74) 49.75 ± 2.22 (28–74) 0.98
BMI (kg/m2) 28.29 ± 0.64 (22.67–35.25) 24.99 ± 0.55 (19.78–30.85) <0.001 ***
Home BP (mmHg)
Home MAP 106.85 ± 1.17 (95.61–121.50), n = 26 87.21 ± 0.92 (75.06–94.72) <0.001 ***
Home SBP 144.83 ± 1.82 (125.67–162.33), n = 26 121.08 ± 1.19 (105.17–130.50) <0.001 ***
Home DBP 87.85 ± 1.28 (78.33–103.00), n = 26 70.27 ± 1.011 (60.00–79.33) <0.001 ***
Study BP (mmHg)
Study MAP 115.96 ± 1.84 (103.50–139.89) 93.88 ± 1.41 (75.33–104.56) <0.001 ***
Study SBP 153.70 ± 2.65 (129.33–189.67) 127.39 ± 1.67 (109.33–139.67) <0.001 ***
Study DBP 97.08 ± 1.58 (84.67–115.00) 77.13 ± 1.46 (58.33–87.67) <0.001 ***
TG (mmol/L) 1.52 ± 0.12 (0.77–3.76), n = 27 1.10 ± 0.09 (0.36–2.35), n = 27 0.007 **
TC (mmol/L) 5.67 ± 0.16 (4.11–7.18), n = 27 5.22 ± 0.23 (3.30–7.79), n = 27 0.12
LDL-C(mmol/L) 3.91 ± 0.16 (2.33–5.19), n = 27 3.48 ± 0.22 (1.73–6.53), n = 27 0.11
HDL-C (mmol/L) 1.43 ± 0.07 (0.93–2.22), n = 27 1.59 ± 0.06 (0.92–2.21), n = 27 0.11
LDL-C/HDL-C 2.88 ± 0.16 (1.32–4.32), n = 27 2.26 ± 0.16 (1.05–4.35), n = 27 0.010 *
TC/HDL-C 4.14 ± 0.19. (2.38–5.77), n = 27 3.41 ± 0.19 (2.01–5.49), n = 27 0.009 **
HbA1c (mmol/mol) 35.59 ± 0.82 (26–43), n = 27 36.59 ± 0.57 (31–42), n = 27 0.28
D-dimer (µg/L) 375.37 ± 40.73 (45–955), n = 27 440.82 ± 72.56 (45–1616) 0.77
IL-6 (pg/mL) 0.63 ± 0.07 (0.16–1.85), n = 27 0.37 ± 0.03 (0.15–0.76) <0.001 ***
Time between baseline and follow-up
assessments (months) 40.75 ± 2.14 (28–61) 39.33 ± 1.81 (28–63) 0.62
Creatinine (µmol/L) 80.48 ± 1.63 (66–93), n = 27
Sodium (mmol/L) 140.39 ± 0.50 (135–145), n = 23
Calcium (mmol/L) 2.40 ± 0.02 (2.17–2.58), n = 23
Potassium (mmol/L) 4.11 ± 0.04 (3.9–4.7), n = 23
Notes. Values are means ± SEM (range); BMI = body mass index; BP = blood pressure; MAP = mean arterial blood pressure; DBP = diastolic
blood pressure; SBP = systolic blood pressure; TG = triglycerides; TC = total cholesterol; LDL-C = low-density lipoprotein cholesterol;
HDL-C = high-density lipoprotein cholesterol; HbA1c = hemoglobin A1c; IL-6 = interleukin-6. Deviating participant numbers are indicated.
* p < 0.05; ** p < 0.01; *** p < 0.001.
2.6. Statistical Analyses
Statistical analyses were performed using SPSS (Version 26.0) statistical software
packages for MacIntosh (IBM SPSS Statistics, Chicago, IL, USA). All tests were two-tailed
with level of significance at p < 0.05 and p-values < 0.10 interpreted as borderline significant.
G*Power (Version 3.1.9.6; Heinrich Heine University Düsseldorf, Germany) analysis
suggests that a total sample size of n = 54 is needed to detect group differences in plasma
lipid stress reactivity (5 repetitions) with a small-to-medium effect size of f = 0.15 in general
models with repeated measures with a power of 0.85, α = 0.05, given the previously
observed minimum intercorrelation among repeated measures of 0.63 and ε = 0.79 [33].
We corrected all plasma lipid levels for stress hemoconcentration following previous
methods by computing stress-induced changes in plasma volume (i.e., stress hemoconcen-
tration) from hemoglobin and hematocrit measures according to the formula by Dill and
Costill [34,35]. Body mass index (BMI) was calculated by the formula BMI = kg/m2.
Univariate analyses of variance (ANOVAs) were used to compute group differences in
participant characteristics. To test for MIST-induced increases in the studied measures, we
calculated ANOVAs with repeated measures for cortisol (baseline, 1 min, 10 min, 20 min,
30 min, 45, min, and 60 min post-stress) and blood lipids (baseline, 1 min, 10 min, 20 min,
and 60 min post-stress) over all participants. Significant changes of each measurement
from baseline were identified post hoc.
As main analyses, we first investigated whether hypertensives exhibited higher blood
lipid increases to acute stress compared with normotensives. We calculated repeated-
measures ANCOVAs with repeated assessment of hemoconcentration-corrected blood
lipids (baseline, 1 min, 10 min, 20 min, and 60 min post-stress) as dependent variables
and with group as the independent variable. Repeated measures ANCOVAs were also
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calculated to examine possible group differences in cortisol (baseline, 1 min, 10 min, 20
min, 30 min, 45, min, and 60 min post-stress). We controlled for age and BMI as covariates
in the repeated-measures ANCOVAs. Post hoc testing of significant stress effects in cortisol
and blood lipid measures comprised univariate ANOVAs with group as the independent
variable and the respective single measurements as dependent variables.
We performed prospective analyses to shed light on the potential clinical relevance
of blood lipid stress reactivity and analyzed whether blood lipid stress responses would
predict future changes in CVD risk factors. We calculated multiple analyses of variance
(MAN(C)OVA) with aggregated blood lipid stress reactivity calculated as area under the
curve with respect to ground (AUCG) [36] as independent variable. Dependent variables
were prospective changes in TC/HDL-C ratio, D-dimer, HbA1c, and IL-6 from baseline
to follow-up assessment (follow-up measurement of the respective parameter minus its
baseline measurement) to investigate CVD risk as dependent variable. Baseline age, MAP,
and time between baseline and follow-up assessments were controlled as a set of covariates
in complementary analyses, in addition to BMI, prospective changes in BMI and MAP, or
medication intake at follow-up assessment. Post hoc testing comprised linear regression
analyses with the aggregated blood lipid stress reactivity (AUCG) as independent variable
and changes in CVD risk factors separately (i.e., changes in TC/HDL-C ratio, D-dimer,
HbA1c, and IL-6) as dependent variables, while controlling for the set of confounders, i.e.,
covariates.
All data were tested for normal distribution and homogeneity of variance using
Kolmogorov–Smirnov and Levene’s tests prior to statistical analyses. All measures showing
a skewed distribution (home MAP and SBP, stress reactivity of cortisol and most TG levels,
HbA1c, IL-6, and D-dimer at baseline as well as prospective changes in TC/HDL-C ratios,
HbA1c, IL-6, BMI, and MAP) were log-transformed. While log-transformed data were
used for modeling and testing, we depict untransformed data in all Tables and Figures for
reasons of clarity. Blood lipids stress reactivity was depicted as (percentage) changes from
baseline to post-stress.
We applied Huynh–Feldt correction for repeated measures where appropriate. We
determined f from partial η2 values using G*Power. Effect size parameters f (effect size
conventions f : 0.10 = small; 0.25 = medium; 0.40 = large) and R2 changes (effect size conven-
tions ∆R2: 0.02 = small; 0.13 = medium; 0.26 = large) are reported where appropriate [37].
3. Results
3.1. Group Characteristics
Table 1 shows the demographic, medical, and psychological characteristics of the 28
hypertensive and 28 normotensive participants. As expected, hypertensives showed higher
systolic and diastolic BP as well as MAP, higher BMI, IMT, IL-6, and fasting TG, as well
as higher LDL-C/HDL-C and TC/HDL-C ratio at baseline (i.e., on the first study day)
compared with normotensives (p-values ≤ 0.010).
Hypertensives had also a higher MIST baseline TC/HDL-C-ratio than normoten-
sives (p = 0.023) did, but there were no other differences in MIST baseline blood lipid
levels (p-values ≥ 0.11; see Table 2). At follow-up, eight of the initially medication-free
participants were under medication: five hypertensives and one normotensive took BP-
lowering medication, one hypertensive took cholesterol-lowering medication, and another
hypertensive participant took uric acid-lowering medication.
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(n = 28) p
Cortisol (nmol/L) 7.22 ± 0.92 (1.83–17.85) 5.21 ± 0.50 (1.61–12.50) 0.16
HDL-C (mmol/L) 1.25 ± 0.06 (0.87–1.93) 1.35 ± 0.05 (0.86–1.83) 0.20
LDL-C (mmol/L) 3.31 ± 0.15 (1.63–4.51) 2.95 ± 0.16 (1.36–5.37) 0.11
TG (mmol/L) 1.66 ± 0.14 (0.61–3.61) 1.38 ± 0.11 (0.35–2.87) 0.12
TC/HDL-C 4.14 ± 0.19 (2.46–6.29) 3.54 ± 0.17 (2.13–5.65) 0.023 *
Notes. Values are means ± SEM (range); HDL-C = high-density lipoprotein cholesterol; LDL-C = low-density
lipoprotein cholesterol; TG = triglycerides; TC = total cholesterol. * p < 0.05.
Participants who dropped out (n = 21) did not significantly differ in any group char-
acteristic (p-values ≥ 0.15; see Appendix A, Table A1) from participants completing both
baseline and follow-up assessment (n = 35).
3.2. Cortisol and Blood Lipid Reactivity to the MIST in All Participants
3.2.1. Cortisol
As a manipulation check, we tested whether the MIST successfully induced cor-
tisol stress reactivity as observed in previous research [22] (see Figure 1A). Across all
participants, the MIST induced significant increases in cortisol (main effect of stress:
F(2.88, 152.86) = 70.39, p < 0.001, partial η2 = 0.57, f = 1.15), with highest levels observed
10 min after MIST cessation. Post hoc testing revealed significant increases from MIST
baseline to 1 min (p < 0.001), 10 min (p < 0.001), 20 min (p < 0.001), 30 min (p < 0.001), and
45 min (p < 0.001) after MIST cessation.
3.2.2. Blood Lipids
As shown in Figure 1B, the MIST induced in all participants significant increases in
HDL-C (main effect of stress: F(3.50, 192.70) = 2.62, p = 0.043, partial η2 = 0.05, f = 0.22)
and LDL-C levels (main effect of stress: F(2.95, 161.96) = 3.53, p = 0.017, partial η2 = 0.06,
f = 0.25), while increases in TC levels did not reach statistical significance (p = 0.13). In
contrast, TG levels decreased in all participants (main effect of stress: F(2.0, 109.70) = 5.01,
p = 0.008, partial η2 = 0.08, f = 0.30). The TC/HDL-C ratio increased after stress, with
highest ratios immediately after stress cessation (main effect of stress: F(2.46, 135.38) = 6.62,
p < 0.001, partial η2 = 0.11, f = 0.35) (see Figure 1C). Compared to baseline, post hoc testing
revealed significant increases in TC/HDL-C ratio immediately (p = 0.017) and 10 min
after stress (p = 0.028), whereas TG levels decreased immediately after stress cessation
(p = 0.044).
3.3. Reactivity to the MIST in Hypertensives as Compared to Normotensives
3.3.1. Baseline
At MIST baseline (see Table 2), hypertensives had higher TC/HDL-C ratio (p = 0.023)
but did not differ in cortisol (p = 0.16) or other blood lipid (p-values ≥ 0.11) levels.
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ately after stress cessation (main effect of stress: F(2.46, 135.38) = 6.62, p < 0.001, partial η2 = 
0.11, f = 0.35) (see Figure 1C). Compared to baseline, post hoc testing revealed significant 
increases in TC/HDL-C ratio immediately (p = 0.017) and 10 min after stress (p = 0.028), 
whereas TG levels decreased immediately after stress cessation (p = 0.044). 
3.3. Reactivity to the MIST in Hypertensives as Compared to Normotensives 
3.3.1. Baseline 
At MIST baseline (see Table 2), hypertensives had higher TC/HDL-C ratio (p = 0.023) 
but did not differ in cortisol (p = 0.16) or other blood lipid (p-values ≥ 0.11) levels. 
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0.017; +60 min: p = 0.013) and thus a lower decline in TG levels after stress cessation. The 
reactivity difference in TG between hypertensives and normotensives was confirmed in 
complementary analyses using MAP as continuous dependent variable (interaction MAP-
by-time: F(2.14, 111.37) = 4.36, p = 0.013, partial η2 = 0.08, f = 0.29). Stress-induced reactivity 
Figure 1. (A–C). Cortisol and blood lipid changes in response to the MIST. Values are means ± SEM. (A) Cortisol.
(B) Percentage changes from baseline to post-stress in TC, TG, LDL-C, and HDL-C. (C) TC/HDL-C ratio changes from
baseline in response to MIST. Asterisks indicate significant differences between baseline and the respective post-stress levels
* p < 0.05; *** p < 0.001.
3.3.2. Reactivity
In terms of blood lipids, hypertensives and normotensives significantly differed in the
stress response of the TC/HDL-C ratio (interaction group-by-time: F(2.79, 145.41) = 4.09,
p = 0.010, partial η2 = 0.07, f = 0.28). Hypertensives showed a higher TC/HDL-C ratio
in respons to stress compared with normotensive me (see Figure 2A and Table A2) at
all post-str s measurements (+1 in: p = 0.009; +10 min: p = 0. 10; +20 min: p = 0.010;
+60 min: p = 0.011). Complementary nalyses u ing MAP instead of group confirmed higher
TC/HDL-C atio stress reactivity with increa ing MAP (interaction MAP-by-time: F(2.73,
14 .76) = 2.25, p = 0.091, partial η2 = 0.04, f = 0.21). The two groups differed also i their
stress-induced TG reactivi y ( nteraction group-by-time: F(2.15, 111.59) = 3.02, p .049,
partial η2 = 0.06, f = 0.24) (see Figure 2B). Compared with n rmotensives, hypertensives
showed higher TG levels (Figure 2B) (+1 min: p = 0.034; +10 min: p = 0.027; +20 min:
p = 0.017; +60 min: p = 0.013) and hus a lower decline in TG levels after stress cessation.
The reactivity difference in TG between hypertensives and normotensives was confirmed
in complementary analyses using MAP as continuous dependent variable (interaction
MAP-by-time: F(2.14, 111.37) = 4.36, p = 0.013, partial η2 = 0.08, f = 0.29). Stress-induced
reactivity in TC (p = 0.71), in HDL-C (p = 0.65), and in LDL-C (p = 0.60) did not differ
between groups. There were no group differences in terms of cortisol reactivity to the MIST
(p = 0.12).
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Figure 2. Blood lipid reactivity to the IST in hypertensive and nor otensive en. alues are means ± . ( ) I -
induced TC/ li . . .
3.4. Prediction of CVD Risk Factors
MANOVA revealed that higher aggregated TC/HDL-C stress reactivity (AUCG) sig-
nificantly predicted increased CVD risk in terms of increases in the measured CVD risk
factors from baseline to follow-up (main effect in multivariate testing: F(4, 30) = 2.95,
p = 0.036, partial η2 = 0.28, f = 0.62, Wilk’s Λ = 0.72). Complementary MANCOVA analyses
controlling for age, MAP, and time between baseline and follow-up assessments as covari-
ates confirmed the main effect of TC/HDL-C stress reactivity as a predictor of increased
CVD risk over time (F(4, 27) = 3.35, p = 0.024, partial η2 = 0.33, f = 0.70, Wilk’s Λ = 0.67).
Additional controlling for BMI, changes in BMI and MAP over time, or medication-intake
at follow-up did not alter the significance of this main effect (p-values ≤ 0.029).
Post hoc testing revealed that higher blood lipid stress reactivity in terms of TC/HDL-
C AUCG predicted greater increases from baseline to follow-up in D-dimer (without
control: ß = 0.33, p = 0.050, ∆R2 = 0.11, Figure 3A; controlling for the set of covariates:
p = 0.11; additional controlling for medication intake, BMI, BMI change, or MAP change:
p-values ≥ 0.09), HbA1c (without control: ß = 0.34, p = 0.046, ∆R2 = 0.12, Figure 3B;
controlling for the set of covariates: ß = 0.32, p = 0.32, ∆R2 = 0.15; additional controlling for
medication intake, BMI, BMI change, or MAP change: p-values ≥ 0.32), and IL-6 (without
control: ß = 0.31, p = 0.075, ∆R2 = 0.09, Figure 3C; controlling for the set of covariates:
ß = 0.45, p = 0.019, ∆R2 = 0.24 additional controlling for medication intake, BMI, BMI
change, or MAP change: ß-values ≥ 0.43, p-values ≤ 0.026, ∆R2 ≥ 0.24). Prediction
of higher TC/HDL-C increases was not significant (p = 0.57) but became of borderline
significance when controlling for the set of covariates (ß = 0.23, p = 0.064, ∆R2 = 0.58;
additional controlling for medication intake, BMI, BMI change, or MAP change: ß-values
≥ 0.25, p-values ≤ 0.073, ∆R2 ≥ 0.59).
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Figure 3. Higher aggregated TC/HDL-C stress reactivity (AUCG) significantly predicted higher increases from baseline to
follow-up in CVD risk factors: (A) D-dimer (ß = 0.33, p = 0.050, ∆R2 = 0.11); (B) HbA1c (ß = 0.34, p = 0.046, ∆R2 = 0.12);
(C) IL-6 (ß = 0.31, p = 0.075, ∆R2 = 0.09).
4. Discussion
The main objective of our study was to investigate whether acute psychosocial stress
induced by the MIST would relate to changes in blood lipid levels (i.e., TC, HDL-C, LDL-C,
TG, and TC/HDL-C ratio) with expected reactivity differences between hypertensive and
normotensive participants. We were further interested in the clinical relevance of blood
lipid stress responses and tested whether TC/HDL-C stress reactivity would prospectively
predict changes in CVD risk factors.
Our results confirm that stress induction by means of the MIST was successful, as
indicated by salivary cortisol increases in line with previous MIST studies [22]. Moreover,
we could extend the stress-provoking potential of the MIST for the first time to blood lipids.
Independent of hemoconcentration, we observed significant increases in HDL-C, LDL-C,
as well as in TC/HDL-C ratio scores in response to the MIST. The observed increases
in atherogenic lipids are in line with previous studies using other potent stressors while
correcting for hemoconcentration effects [15–17]. Interestingly, in our study, TG levels
decreased after stress induction. Because triglycerides serve as energy reserves, we assume
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that the decrease in triglycerides after stress may represent a process of energy supply in
reaction to stress-induced increased energy expenditure [38].
With respect to group differences, hypertensives showed a more pronounced rise
in TC/HDL-C ratio scores and a slower decrease in TG levels in response to the MIST
compared with normotensive participants. Complementary analyses using MAP confirmed
the linear nature of this effect. The observed stress-related changes in atherogenic lipids
resemble our previous observations in a TSST study [17]. We interpret our findings to mean
that with increasing BP, hypertensives seem to be more vulnerable to acute psychosocial
stress in terms of blood lipid responses. Group differences in stress-induced blood lipid
reactivity might be elicited by the metabolic effect of catecholamine spillover in sympathetic
nerve endings and from the adrenal medulla in response to acute psychosocial stress [17,39].
Increases in circulating catecholamines can induce lipolysis and release free fatty acids into
the circulation [39]. With respect to cortisol analyzed in our study, stress induction by means
of the MIST did not result in group differences between hypertensives and normotensives
as observed in our previous TSST study [40]. We assume that the differences in stress-
evoking components between the MIST and the TSST may account for this discrepancy. We
performed the MIST in an MRT scanner, and the MRT experience may constitute part of
the MIST stress experience that is not psychosocial in nature. Moreover, the direct contact
with the experimenter is lower in the MRT scanner-based MIST as compared to the TSST
with its permanent social confrontation. If the cortisol stress hyperreactivity observed in
hypertensive participants mainly results from psychosocial stress aspects, their reactivity
to the MIST might be comparably lower. At the same time, it is possible that normotensive
participants may react stronger to the MIST, especially if performed within the potentially
intimidating surrounding of an MRT scanner, as to the primarily psychosocial TSST.
Our prospective analyses were aimed to shed light on the supposed clinical relevance
of blood lipid stress reactivity. Indeed, we found evidence for blood lipid stress reactivity
in predicting future CVD risk in terms of increases over time in the intermediate biological
risk factors HbA1c, D-dimer, and Il-6, and in part also in the TC/HDL-C ratio. Notably,
one hypertensive participant started intake of cholesterol-lowering medication between
baseline and follow-up assessment, and exclusion of this participant from analyses did
not significantly change the observed prediction (data not shown). Given the observed
higher blood lipid stress reactivity with increasing hypertension, our prospective findings
suggest that blood lipid stress reactivity may play a role in mediating future CVD risk in
hypertensives. We offer several possible explanations for these findings: (1) Atherosclerosis
with its underlying process of chronic inflammation is central to CVD [41,42]. We speculate
that increases in blood lipids, even if transient, may promote atherosclerosis by acutely
forcing blood lipids into the arterial wall, thus adding to lipid accumulation in the intima-
media of the carotid arteries. Increased lipid accumulation in the arterial wall of carotid
arteries may relate to increased amounts of oxidized lipids, which in turn promote both
inflammatory and atherothrombotic processes in atherosclerosis [41,42]. In line with such
reasoning, we observed higher lipid stress reactivity to predict higher prospective IL-6 and
fibrin D-dimer increases. At the same time, both IL-6 and fibrin D-dimer are independent
CVD risk factors that can further promote atherosclerotic processes [25,26,43]. (2) Our
borderline significant finding of blood lipid stress reactivity independently predicting
increased TC/HDL-C ratio over time confirms a previous study by Steptoe et al. [24].
Extending these prior results, our data suggest that this association seems to be independent
of hemoconcentration effects. In line with the allostatic load model, we speculate that
repeated stressful experiences may accumulate over time to result in chronic elevations of
blood lipid levels [44], but the precise underlying mechanism warrants further investigation.
(3) Diabetic dyslipidemia is a well-known phenomenon, especially in the context of the
metabolic syndrome clustering increased BP, high blood sugar, and dyslipidemia [45].
However, potential mechanisms underlying our finding of blood lipid stress responses to
predict increases in HbA1c as an indicator of increased blood sugar over time are unclear.
Notably, our observed associations were not independent of confounders, in particular of
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basal MAP, suggesting that basal BP effects may play a role in modulating the observed
HbA1c increases.
Limitations of our study are the relatively small number of participants due to the
experimental nature of our study and the comparably high drop-out rate that we mainly
attribute to organizational reasons. While the participant number for our stress study
was based on our a priori sample size calculations allowing to detect effects of small-to-
medium effect sizes, the reduced sample size available for the prospective analyses only
allowed to detect medium-to-large effects. We therefore cannot rule out the possibility
that the study was underpowered to detect smaller effects and that our results might be
biased. Notably, given our follow-up sample size, we only allowed for a maximum of
four confounders in follow-up analyses [46]. Although participants who dropped out
did not substantially differ in their characteristics at baseline from those completing the
follow-up assessment, there were more drop-outs in the hypertensive group. Furthermore,
eight participants started medication intake between baseline and follow-up assessment,
which could possibly influence prospective outcomes, although we controlled for potential
medication effects. Finally, the generalizability of our results is limited to middle-aged
normotensive and essentially hypertensive men.
5. Conclusions
Taken together, we observed significant changes in blood lipid levels in reaction
to stress induction by means of the MIST. Blood lipid levels were higher after stress in
hypertensive individuals compared with normotensive controls and also with increasing
MAP. As the aggregated TC/HDL-C stress reaction predicted CVD risk factors several
years later, blood lipid stress reactivity might be a potential mechanism contributing to
a poorer cardiovascular health in hypertensives. Future studies are needed to replicate
our cross-sectional and in particular prospective findings in larger sample sizes including
women and clinical populations. Subsequent studies could further investigate whether
specific medication (e.g., statin therapy) could attenuate the effects of stress on lipid levels.
Moreover, the mechanisms underlying the observed stress-reactivity differences between
hypertensives and normotensives and the prospective associations between blood lipid
stress reactivity and CVD risk warrant further investigation.
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Appendix A
Table A1. Comparison of baseline group characteristics between participants completing follow-up




(n = 21) p
Age (years) 50.20 ± 1.91 (28–74) 49.10 ± 2.45 (25–69) 0.72
BMI (kg/m2) 26.37 ± 0.62 (19.78–34.58) 27.08 ± 0.73 (22.67–35.25) 0.47
Home BP (mmHg)
Home MAP 96.17 ± 2.14 (75.06–121.50) 97.34 ± 2.21 (82.39–110.94) 0.66
Home SBP 131.04 ± 2.63 (105.17–162.33) 135.03 ± 2.75 (115.17–154.50) 0.29
Home DBP 78.77 ± 1.90 (60–103) 78.68 ± 2.25 (62.83–91.17) 0.98
Study BP (mmHg)
Study MAP 103.73 ± 2.58 (75.33–139.89) 106.90 ± 2.57 (79.83–126.56) 0.42
Study SBP 139.39 ± 3.18 (109.33–189.67) 142.48 ± 3.44 (112.5–166.33) 0.53
Study DBP 85.90 ± 2.37 (58.33–115) 89.11 ± 2.32 (63.50–108.00) 0.37
TG (mmol/L) 1.38 ± 0.11 (0.36–3.76) 1.15 ± 0.07 (0.71–1.88) 0.15
TC (mmol/L) 5.36 ± 0.16 (3.30–7.69) 5.60 ± 0.27 (3.90–7.79) 0.41
LDL-C (mmol/L) 3.61 ± 0.14 (1.73–5.69) 3.82 ± 0.27 (2.09–6.53) 0.45
HDL-C (mmol/L) 1.49 ± 0.06 (0.92–2.21) 1.58 ± 0.09 (1.08–2.22) 0.35
LDL-C/HDL-C 2.57 ± 0.14 (1.05–3.97) 2.57 ± 0.23 (1.07–4.35) 0.98
TC/HDL-C 3.78 ± 0.17 (2.01–5.49) 3.72 ± 0.25 (2.03–5.77) 0.79
HbA1c (mmol/mol) 36.26 ± 0.63 (28–43) 35.79 ± 0.83 (26–40) 0.67
D-dimer (µg/L) 416.43 ± 59.05 (45–1616) 395.15 ± 52.52 (45–955) 0.98
IL-6 (pg/mL) 0.47 ± 0.04 (0.15–1.25) 0.55 ± 0.08 (0.21–1.85) 0.37
Notes. Values are means ± SEM (range); BMI = body mass index; BP = blood pressure; MAP = mean arterial
blood pressure; DBP = diastolic blood pressure; SBP = systolic blood pressure; TG = triglycerides; TC = total
cholesterol; LDL-C = low-density lipoprotein cholesterol; HDL-C = high-density lipoprotein cholesterol; HbA1c =
hemoglobin A1c; IL-6 = interleukin-6.




(n = 28) p
TC/HDL-C
−1 min 4.14 ± 0.19 (2.46–6.29) 3.54 ± 0.17 (2.13–5.65) 0.023 *
+1 min 4.24 ± 0.20 (2.45–6.28) 3.54 ± 0.17 (2.15–5.51) 0.009 **
+10 min 4.24 ± 0.20 (2.44–6.52) 3.54 ± 0.17(2.16–5.62) 0.010 *
+20 min 4.22 ± 0.20 (2.43–6.26) 3.53 ± 0.17 (2.17–5.53) 0.010 *
+60 min 4.20 ± 0.20 (2.42–6.14) 3.51 ± 0.17 (2.12–5.58) 0.011 *
TG (mmol/L)
−1 min 1.66 ±0.14 (0.61–3.61) 1.38 ± 0.11 (0.35–2.87) 0.121
+1 min 1.61 ± 0.13 (0.62–3.44) 1.24 ± 0.09 (0.37–2.21) 0.022 *
+10 min 1.60 ± 0.13 (0.67–3.44) 1.24 ± 0.10 (0.39–2.30) 0.027 *
+20 min 1.63 ± 0.13 (0.68–3.22) 1.23 ± 0.09 (0.39–2.30) 0.014 *
+60 min 1.65 ± 0.13 (0.71–3.41) 1.24 ± 0.09 (0.39–2.29) 0.013 *
TC (mmol/L)
−1 min 4.97 ± 0.17 (3.16–6.53) 4.63 ± 0.18 (2.69–7.01) 0.18
+1 min 4.95 ± 0.18 (3.29–6.60) 4.66 ± 0.18 (2.80–7.05) 0.25
+10 min 4.99 ± 0.19 (3.20–7.13) 4.76 ± 0.19 (2.87–7.21) 0.39
+20 min 5.03 ± 0.19 (3.26–7.16) 4.66 ± 0.18 (2.77–7.15) 0.16
+60 min 5.03 ± 0.19 (3.20–6.93) 4.73 ± 0.19 (2.79–7.41) 0.26
HDL (mmol/L)
−1 min 1.25 ± 0.06 (0.87–1.93) 1.35 ± 0.05 (0.86–1.83) 0.20
+1 min 1.21 ± 0.05 (0.80–1.96) 1.35 ± 0.05 (0.83–1.82) 0.06
+10 min 1.23 ± 0.07 (0.67–2.02) 1.38 ± 0.05 (0.86–1.78) 0.09
+20 min 1.24 ± 0.06 (0.87–1.97) 1.36 ± 0.05(0.83–1.79) 0.14
+60 min 1.24 ± 0.06 (0.86–2.01) 1.38 ± 0.05 (0.86–1.88) 0.08
LDL (mmol/L)
−1 min 3.31 ± 0.15 (1.63–4.51) 2.95 ± 0.16 (1.36–5.37) 0.11
+1 min 3.30 ± 0.16 (1.71–4.61) 2.92 ± 0.18 (0.57–5.48) 0.13
+10 min 3.31 ± 0.16 (1.67–5.00) 3.06 ± 0.17 (1.43–5.59) 0.27
+20 min 3.36 ± 0.16 (1.73–4.99) 3.00 ± 0.16 (1.39–5.58) 0.13
+60 min 3.38 ± 0.16 (1.72–5.04) 3.06 ± 0.17 (1.42–5.64) 0.18
Notes. Values are means ± SEM (range); TC = total cholesterol; HDL-C = high-density lipoprotein cholesterol; TG
= triglycerides; LDL-C = low-density lipoprotein cholesterol. * p < 0.05; ** p < 0.01.
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